RxDoctor Payments Data

Ashley Cott, APRN

Psychiatric/Mental Health · Kansas City, MONPI 1053781120

Payments from drug & device makers

$3,850in general payments, 2019–2025

Across 228 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$728
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$631
  • Teva Pharmaceuticals USA, Inc.$571
  • Alkermes, Inc.$423
  • Otsuka America Pharmaceutical, Inc.$318
  • Neurocrine Biosciences, Inc.$204
  • plus $976 from 8 others

What the payments were for

  • Food & beverage$3,69896%
  • Education$1514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,850 in reported general payments places this provider in the 80th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$8,153
Medicare patients
30
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil68$207,441
Invega SustennaPaliperidone Palmitate64$194,667
RexultiBrexpiprazole70$105,162
IngrezzaValbenazine Tosylate13$103,257
Abilify MaintenaAripiprazole27$80,019
CaplytaLumateperone Tosylate33$59,587
VraylarCariprazine Hcl40$58,792
LybalviOlanzapine/Samidorphan Malate19$31,929
SecuadoAsenapine19$27,631
TrintellixVortioxetine Hydrobromide42$21,442
Lurasidone Hcl67$17,996
Paliperidone ErPaliperidone25$17,503
BelsomraSuvorexant19$8,856
Aripiprazole75$4,341
Duloxetine Hcl185$4,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada, Lybalvi$423$239,37087 claims
Johnson & JohnsonInvega Sustenna$145$194,66764 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$318$185,18297 claims
Neurocrine Biosciences, Inc.Ingrezza$204$103,25713 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$631$59,58733 claims
AbbVieVraylar$728$58,79240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →